Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Glassman

Obstetrics & Gynecology Phoenix, AZ Doctor of Osteopathy

NPI 1194799320 CMS profile 280658

4444 N 32Nd St, Ste 220, Phoenix, AZ 85018

Open in the dashboard

General payments

$89,898

277 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Glassman of Phoenix, AZ is reported in the CMS Open Payments database as having received $89,898 across 277 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,742 47
2024 General $7,340 39
2023 General $19,512 51
2022 General $20,351 62
2021 General $5,174 33
2020 General $15,116 24
2019 General $9,663 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Glassman
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to David Glassman were reported at $12,742. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year David Glassman Obstetrics & Gynecology median Middle half National median
2019 $9,663 $172 $62–$391 $163
2020 $15,116 $94 $36–$222 $114
2021 $5,174 $136 $42–$369 $132
2022 $20,351 $160 $50–$433 $149
2023 $19,512 $169 $56–$423 $160
2024 $7,340 $152 $50–$371 $164
2025 $12,742 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Minerva Surgical, Inc $34,061 82 payments
  2. AbbVie, Inc. $27,953 39 payments
  3. Intuitive Surgical, Inc. $21,556 21 payments
  4. CooperSurgical, Inc. $1,126 14 payments
  5. Merz North America, Inc. $592 7 payments
  6. Sumitomo Pharma America, Inc. $497 16 payments
  7. Organon LLC $406 8 payments
  8. Boston Scientific Corporation $370 3 payments
  9. Aroa Biosurgery Incorporated $233 2 payments
  10. Baxter Healthcare $225 4 payments
  11. Other $2,878 81 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $49,563 36 payments
  2. Education $20,000 5 payments
  3. Food and Beverage $11,922 207 payments
  4. Travel and Lodging $7,164 27 payments
  5. Consulting Fee $1,250 2 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $21,556 21 payments
  2. ORIAHNN $9,990 12 payments
  3. Orilissa Endocrinology $8,960 13 payments
  4. ORILISSA Womens Health $8,868 12 payments
  5. Advincula Delineator Uterine Manipulator $383 4 payments
  6. MYFEMBREE Hormone Therapy $344 12 payments
  7. MYFEMBREE Womens Health $258 9 payments
  8. Summit Doppler $247 2 payments
  9. Xeomin musculoskeletal $229 2 payments
  10. Xeomin Dermatology $226 3 payments
  11. Other $5,364 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

28

Median for Obstetrics & Gynecology: 65

Drug cost

$998

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

100%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol (Twice Weekly) Estradiol Brand 15 $790
Progesterone Progesterone, Micronized Brand 13 $208

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$22,759

Medicare's payments for the services billed

Medicare patients

63

Average age 70

Services billed

194

63 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 51%
Arthritis 49%
Osteoporosis 22%
Chronic kidney disease 19%
Depression 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $134
$134 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $75
  • PFIZER INC. $3
$78 — —
SLYND
  • Exeltis, USA Inc. $17
$17 — —
FEMRING
  • MILLICENT US INC $11
$11 — —
INTRAROSA
  • MILLICENT US INC $11
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

277 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record